Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Lung Cancer

Free Subscription 17.11.2025 4 BMC Cancer 2 Br J Cancer 5 Cancer Lett 1 Carcinogenesis 1 Clin Lung Cancer 1 Eur J Cancer 1 Eur J Cardiothorac Surg 1 Eur Respir J 1 Int J Cancer 1 J Cancer Res Clin Oncol 1 J Comput Assist Tomogr 2 J Natl Cancer Inst 9 J Thorac Oncol 2 Lancet Oncol 18 Lung Cancer 1 Nat Genet 1 Oncogene 1 Oncologist

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BMC Cancer

1. KE Z, Xu H, Shen K, Wen Y, et al
   KAT2A: a prognostic biomarker influencing proliferation and immune escape in lung adenocarcinoma.
   BMC Cancer. 2025;25:1753.
   PubMed         Abstract available
   
   
2. LI H, Ding L, Li N, Hong X, et al
   Unraveling the nexus between lung cancer and rheumatoid arthritis using integrative transcriptomics and genomics.
   BMC Cancer. 2025;25:1758.
   PubMed         Abstract available
   
   
3. CHEN Z, Wang Y, Shi M, Qi K, et al
   Risk factors and predictive model of lymph node metastasis in clinical stage IA peripheral non-small cell lung cancer: a retrospective study.
   BMC Cancer. 2025;25:1742.
   PubMed         Abstract available
   
   
4. WANG Y, Su Y, Li J, Xie D, et al
   Machine learning-based differentiation of benign and malignant adrenal lesions using 18F-FDG PET/CT: a two-stage classification and SHAP interpretation study.
   BMC Cancer. 2025;25:1726.
   PubMed         Abstract available
   
   

   
   Br J Cancer

5. XIAO Y, Luo Y, Mao D, Zhang L, et al
   Metabolic dysregulation associated with core symptom cluster in lung cancer patients undergoing chemotherapy.
   Br J Cancer. 2025 Nov 13. doi: 10.1038/s41416-025-03262.
   PubMed         Abstract available
   
   
6. HAMZA A, Gestraud P, Karimi M, Tran-Dien A, et al
   Molecular analysis of lung adenocarcinomas from the SAFIR02-Lung cohort reveals new metastasis-associated copy-number alterations including frequent mutant-specific KRAS-allelic imbalance and identifies CDKN2A homozygous deletions as an independent bi
   Br J Cancer. 2025;133:1554-1564.
   PubMed         Abstract available
   
   

   
   Cancer Lett

7. WANG G, Wang W
   Letter to the editor on 'AI-based radiomic features predict outcomes and the added benefit of chemoimmunotherapy over chemotherapy in extensive stage small cell lung cancer: A multi-institutional study'.
   Cancer Lett. 2025;636:218107.
   PubMed        
   
   
8. HUANG X, Liang J, Yi Y, Zhu J, et al
   Targeting inosine metabolism to enhance EGFR-targeted therapy in lung adenocarcinoma.
   Cancer Lett. 2025;634:218069.
   PubMed         Abstract available
   
   
9. CHEN Y, Wang X, Li H, Zhang Z, et al
   Oncoprotein SND1-enriched exosomes facilitate melanoma lung metastasis by regulating CD47-SIRPalpha-mediated macrophage reprogramming.
   Cancer Lett. 2025 Sep 25:218037. doi: 10.1016/j.canlet.2025.218037.
   PubMed         Abstract available
   
   
10. XIAO C, Fan T, Wang D, Yin H, et al
    RAD21-mediated epigenetic regulation promotes lung adenocarcinoma progression and sensitizes cancer cells to ERK-targeted therapy.
    Cancer Lett. 2025;634:218062.
    PubMed         Abstract available
    
    
11. KUANG Y, Yang S, Tian X, Cheng H, et al
    Hinokitiol preferentially suppresses metastatic lung adenocarcinoma via TMDD1-mediated ferroptosis induction and iron-sulfur cluster inhibition.
    Cancer Lett. 2025;634:218046.
    PubMed         Abstract available
    
    

    
    Carcinogenesis

12. NAKAMICHI S, von Muhlinen N, Yamada L, Melamed JR, et al
    SRSF3 knockdown-induced cellular senescence as a possible therapeutic strategy for non-small cell lung cancer.
    Carcinogenesis. 2025 Nov 12:bgaf082. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

13. ARIZPE A, Nieva J, Liu L, Pickering TA, et al
    Socioecological Factors Associated With Lung Cancer Clinical Trial Participation: Real-world California Cancer Registry Data.
    Clin Lung Cancer. 2025 Oct 22:S1525-7304(25)00277.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

14. ZHANG J, Wang S, Li T, Liu X, et al
    Letter Re: Association of pre-surgical circulating tumor DNA detection, use of sublobar resection with risk of recurrence in stage I non-small cell lung cancer.
    Eur J Cancer. 2025;231:115518.
    PubMed        
    
    

    
    Eur J Cardiothorac Surg

15. BRUNELLI A, Hardavella G, Huber RM, Berghmans T, et al
    European Respiratory Society and European Society of Thoracic Surgeons clinical practice guideline on fitness for curative intent treatment of lung cancer.
    Eur J Cardiothorac Surg. 2025;67:ezaf329.
    PubMed         Abstract available
    
    

    
    Eur Respir J

16. BRUNELLI A, Hardavella G, Huber RM, Berghmans T, et al
    European Respiratory Society and European Society of Thoracic Surgeons clinical practice guideline on fitness for curative intent treatment of lung cancer.
    Eur Respir J. 2025;66:2500156.
    PubMed         Abstract available
    
    

    
    Int J Cancer

17. EIJKELBOOM AH, d'Hooghe JNS, van der Sangen M, van den Heuvel MM, et al
    Income inequalities, tumor stage at diagnosis, and treatment in patients with non-small cell lung cancer: A population-based study in the Netherlands.
    Int J Cancer. 2025 Nov 7. doi: 10.1002/ijc.70230.
    PubMed         Abstract available
    
    

    
    J Cancer Res Clin Oncol

18. SUN C, Ye M, Cao W, Zeng J, et al
    DCN, NPM3 and SULF1 are hub genes related to vasculogenic mimicry in lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2025;151:318.
    PubMed         Abstract available
    
    

    
    J Comput Assist Tomogr

19. LI F, He Y, Yang H, Qu X, et al
    Pseudocavity on Thin-slice CT Can Be a Suggestion of Bronchiolar Adenoma: A Preliminary Study on 80 Cases With Bronchiolar Adenoma of the Lung.
    J Comput Assist Tomogr. 2025;49:934-942.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

20. NUCCIO A, Salomone F, Servetto A, Ricciuti B, et al
    Neoadjuvant vs perioperative chemo-immunotherapy according to pathological response in resectable non-small cell lung cancer: a reconstructed individual patient data meta-analysis.
    J Natl Cancer Inst. 2025;117:2388-2393.
    PubMed         Abstract available
    
    
21. SELLERS ME, Cronin KA, Lowy DR
    Stat Bite: Urban and Rural Lung Cancer Mortality Trends in the United States.
    J Natl Cancer Inst. 2025;117:2417-2418.
    PubMed        
    
    

    
    J Thorac Oncol

22. MIYAKOSHI J, Shiraishi K, Mochizuki A, Tateishi A, et al
    Chromosome 15q15 Deletion Drives Brain Metastasis in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2025 Nov 7:S1556-0864(25)02894.
    PubMed         Abstract available
    
    
23. ADJEI AA
    Lung Cancer in 2025: Advances in Treatment Continue, but Access Remains Unequal.
    J Thorac Oncol. 2025;20:1559-1560.
    PubMed        
    
    
24. ZHOU T, Terry OC, Minton KG, Poole L, et al
    Comprehensive Genomic Profiling of Rare Lung Tumors: Adenosquamous Carcinoma and Pulmonary Carcinosarcoma.
    J Thorac Oncol. 2025;20:1716-1721.
    PubMed         Abstract available
    
    
25. LEE SH, Lu S, Hayashi H, Felip E, et al
    Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSA.
    J Thorac Oncol. 2025;20:1655-1668.
    PubMed         Abstract available
    
    
26. CARBONE M, Minaai M, Kittaneh M, Krausz T, et al
    Clinical and Pathologic Phenotyping of Mesotheliomas Developing in Carriers of Germline BAP1 Mutations.
    J Thorac Oncol. 2025;20:1683-1698.
    PubMed         Abstract available
    
    
27. DAGOGO-JACK I, Mitchell O, Codd E, Li A, et al
    Immune Composition and Immunotherapy Outcomes of Mesothelioma With BAP1, CDKN2A, MTAP, and NF2 Alterations.
    J Thorac Oncol. 2025;20:1615-1625.
    PubMed         Abstract available
    
    
28. MITSUDOMI T, Heymach JV, Reck M, Taube JM, et al
    Surgical Outcomes With Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLC.
    J Thorac Oncol. 2025;20:1639-1654.
    PubMed         Abstract available
    
    
29. AHN MJ, Lisberg A, Goto Y, Sands J, et al
    A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC.
    J Thorac Oncol. 2025;20:1669-1682.
    PubMed         Abstract available
    
    
30. CHO H, Shiraishi K, Sunami K, Momozawa Y, et al
    Genomic Profiles of Pathogenic and Moderate-Penetrance Germline Variants Associated With Risk of Early-Onset Lung Adenocarcinoma.
    J Thorac Oncol. 2025;20:1626-1638.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

31. ROBBINS HA, Johansson M
    Defining eligibility for lung cancer screening based on individual risk.
    Lancet Oncol. 2025 Nov 10:S1470-2045(25)00537.
    PubMed        
    
    
32. VOGEL-CLAUSSEN J, Bollmann BA, May K, Stiebeler S, et al
    Effectiveness of NELSON versus PLCOm2012 lung cancer screening eligibility criteria in Germany (HANSE): a prospective cohort study.
    Lancet Oncol. 2025 Nov 10:S1470-2045(25)00490.
    PubMed         Abstract available
    
    

    
    Lung Cancer

33. CHEN X, Huan C, Yang P, He M, et al
    Immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer patients with preexisting pulmonary emphysema or interstitial lung abnormalities.
    Lung Cancer. 2025;210:108831.
    PubMed         Abstract available
    
    
34. FREHNER L, Schar S, Hayoz S, Petermichl V, et al
    First-line immunotherapy +/- chemotherapy with or without upfront stereotactic radiotherapy (SRT) in patients with Non-Small cell lung cancer (NSCLC) with asymptomatic brain metastases.
    Lung Cancer. 2025;210:108813.
    PubMed         Abstract available
    
    
35. SHOSHIHARA N, Matsumoto K, Shiroyama T, Komuta K, et al
    Long-term survival comparison of first-line pembrolizumab versus pembrolizumab plus chemotherapy for patients with advanced non-small cell lung cancer: A multicenter propensity-matched cohort study.
    Lung Cancer. 2025;210:108835.
    PubMed         Abstract available
    
    
36. UCHIBORI A, Okada S, Shimomura M, Furuya T, et al
    Clinical impact of preoperative adipopenia on postoperative outcomes in non-small cell lung cancer surgery.
    Lung Cancer. 2025;210:108810.
    PubMed         Abstract available
    
    
37. MA W, Zhao B, Lang Y, Liu Z, et al
    The 5-year survival outcomes analysis of EGFR-TKI or/and chemotherapy as initial adjuvant therapy for completely resected IIIA non-small cell lung cancer.
    Lung Cancer. 2025;210:108721.
    PubMed         Abstract available
    
    
38. JUNG HA, Kim TM, Kim HR, Kim CG, et al
    Phase II study of lazertinib and pemetrexed in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer with leptomeningeal metastases: the KCSG LU 21-01, LAZARUS study.
    Lung Cancer. 2025;210:108809.
    PubMed         Abstract available
    
    
39. TANNOURY E, Byrne SC, Hammer MM
    Factors associated with lung cancer-specific mortality in lung cancer screening programs.
    Lung Cancer. 2025;210:108815.
    PubMed         Abstract available
    
    
40. FAEHLING M, Fallscheer S, Schmiederer J, Strater J, et al
    Pattern of brain metastases and survival in lung adenocarcinoma with KRAS or EFGR mutation.
    Lung Cancer. 2025;209:108803.
    PubMed         Abstract available
    
    
41. GOMEZ-RANDULFE I, Monaca F, Cantale O, Reale ML, et al
    Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort study.
    Lung Cancer. 2025;209:108797.
    PubMed         Abstract available
    
    
42. WU X, Wan R, Wu L, Zhao M, et al
    Safety and efficacy of YK-029A in previously treated EGFR T790M-Mutant NSCLC: A multi-center phase I trial.
    Lung Cancer. 2025;209:108764.
    PubMed         Abstract available
    
    
43. MOK T, Nishio M, Yoshida T, Ahn MJ, et al
    Efficacy and safety of brigatinib after alectinib in patients with ALK-positive NSCLC: Integrated analysis of the ALTA-2 and J-ALTA studies.
    Lung Cancer. 2025;209:108793.
    PubMed         Abstract available
    
    
44. AGRAWAL P, Rotow J, Rocco G, Travis W, et al
    Outcomes with neoadjuvant osimertinib and/or chemotherapy in patients with EGFR-mutant resectable non-small cell lung cancers.
    Lung Cancer. 2025;209:108795.
    PubMed         Abstract available
    
    
45. CORTELLINI A, Garbo E, La Cava G, Citarella F, et al
    Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression >/= 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity.
    Lung Cancer. 2025;209:108799.
    PubMed         Abstract available
    
    
46. GENUGTEN JHLTV, Faulkner D, Hahne JC, Poile C, et al
    Discovery of actionable drug targets to enhance T-cell infiltration and immune checkpoint blockade efficacy in pleural mesothelioma.
    Lung Cancer. 2025;209:108769.
    PubMed         Abstract available
    
    
47. VAN DER WEL JWT, Ernst SM, Jebbink M, van den Broek D, et al
    Determining the optimal approach to identify osimertinib resistance; the first line osimertinib cohort of the OSIRIS study.
    Lung Cancer. 2025;209:108783.
    PubMed         Abstract available
    
    
48. BORM FJ, Schelhaas MJ, Steeghs EMP, Timmer CW, et al
    Liquid biopsy in BALF is now suitable for clinical practice in patients with suspected NSCLC.
    Lung Cancer. 2025;209:108771.
    PubMed         Abstract available
    
    
49. LIU M, Townsend JP
    KRAS G12C-associated immunotherapy benefit in NSCLC is substantially mediated by tobacco-induced tumor mutation burden, not allele-specific effects.
    Lung Cancer. 2025;209:108749.
    PubMed         Abstract available
    
    
50. SCHEFFLER M, Tzala L, Louie K, Persigehl T, et al
    Evaluating docetaxel effectiveness in KRAS G12C-mutated NSCLC: insights from a Real-World cohort.
    Lung Cancer. 2025;209:108768.
    PubMed         Abstract available
    
    

    
    Nat Genet

51. CHALABI HAJKARIM M, May M, Amin AD, Jamison J, et al
    Cellular states associated with metastatic organotropism and survival in patients with pancreatic ductal adenocarcinoma.
    Nat Genet. 2025;57:2728-2742.
    PubMed         Abstract available
    
    

    
    Oncogene

52. OGUNLUSI O, Sarkar M, Carter K, Chakrabarti A, et al
    LILRB4 regulates circadian disruption-induced mammary tumorigenesis via non-canonical WNT signaling pathway.
    Oncogene. 2025;44:4491-4504.
    PubMed         Abstract available
    
    

    
    Oncologist

53. VILLARUZ LC, Schluger B, Wang H, Ohr J, et al
    Phase Ib study of berzosertib, carboplatin, gemcitabine, and pembrolizumab in patients with squamous non-small lung cancer (ETCTN 10313).
    Oncologist. 2025 Nov 7:oyaf373. doi: 10.1093.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.